Trial Profile

A phase 3, open-label, safety study of Adapalene/minocycline in subjects with moderate-to-severe acne vulgaris

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 30 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adapalene/minocycline (Primary)
Indications Acne vulgaris
Focus Registrational; Therapeutic Use
Acronyms TRILOGY-3
Sponsors VYNE Therapeutics

Most Recent Events

30 Dec 2020 New trial record
17 Dec 2020 According to a VYNE Therapeutics media release, the company is on track to initiate this TRILOGY Phase 3 program in 2021.
17 Dec 2020 According to a VYNE Therapeutics media release, the FDA has agreed to accept the data from this study after the NDA has been submitted. Based on the data of this study, it is expected that NDA will be enable the to be submitted earlier than originally planned.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com